Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for Injection in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma

NCT05438394 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05438394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05438394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for Injection in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma
Lead sponsor
Peking University People's Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
October 13, 2022
Completion date
December 31, 2023
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma